norelgestromin has been researched along with 17-alpha-hydroxyprogesterone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lelle, I; Prifti, S; Rabe, T; Strowitzki, T; Zhong, G | 1 |
| Lelle, I; Prifti, S; Rabe, T; Strowitzki, T | 1 |
2 other study(ies) available for norelgestromin and 17-alpha-hydroxyprogesterone
| Article | Year |
|---|---|
Matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression is not regulated by norgestimate or norelgestromin.
Topics: 17-alpha-Hydroxyprogesterone; Cell Line, Tumor; Contraceptives, Oral, Combined; Contraceptives, Oral, Synthetic; Drug Combinations; Endometrium; Enzyme-Linked Immunosorbent Assay; Estradiol; Ethisterone; Female; Humans; Matrix Metalloproteinase 2; Norgestrel; Oximes; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2004 |
Induction of androgen receptor activity by norgestimate and norelgestromin in MDA-MB 231 breast cancer cells.
Topics: 17-alpha-Hydroxyprogesterone; Breast Neoplasms; Contraceptives, Oral, Combined; Dihydrotestosterone; Drug Combinations; Ethisterone; Genetic Vectors; Humans; Luciferases; Norgestrel; Oximes; Receptors, Androgen; Testosterone; Transfection; Tumor Cells, Cultured | 2004 |